EUVIMEDEUVIMED entdecken
Crossref

Carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of the phase 2 FORTE trial

Giuseppe Bertuglia, Mattia D'Agostino iD, Delia Rota-Scalabrini iD, Angelo Belotti, Laura Paris, Micol Quaresima, Sonia Morè, Stelvio Ballanti iD, Sara Aquino iD, Paolo De Fabritiis iD, Francesca Fioritoni iD, Michele Cea iD und 13 weitere

Blood Journal · 16.11.2026

DOI: 10.1182/blood.2026035635 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Journal, online erschienen am 16.11.2026. Verfasst von Giuseppe Bertuglia und 24 weiteren Autor:innen. Beteiligte Einrichtung: AOU Città della Salute e della Scienza di Torino, Torino, Italy.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the phase 2 FORTE trial, transplant-eligible newly diagnosed multiple myeloma patients aged ≤65 years were randomized to (R1) carfilzomib-lenalidomide-dexamethasone followed by autologous stem cell transplantation (KRd-ASCT), twelve cycles of KRd (KRd12), or carfilzomib-cyclophosphamide-dexamethasone followed by ASCT (KCd-ASCT). Eligible patients were then randomized (R2) to maintenance with carfilzomib for 2 years plus lenalidomide until progression (KR) or lenalidomide alone until progression (R). With extended follow-up (median 99 months from R1 and 85 months from R2), KRd-ASCT significantly increased progression-free survival (PFS, median 98 months) versus KRd12 (median 70 months; HR 0.71, p=0.027) and KCd-ASCT (median 67 months; HR 0.66, p=0.006). A significant benefit in PFS2 was also observed versus both KRd12 (HR 0.65, p=0.02) and KCd-ASCT (HR 0.68, p=0.04) and in terms of overall survival (OS) versus KCd-ASCT (8-year OS: 76% vs 68%; HR 0.65, p=0.04). KR maintenance significantly improved PFS versus R (HR 0.67, p=0.02), with a time-dependent effect persisting up to two years after carfilzomib discontinuation; no differences in PFS2/OS were observed. KR significantly increased rate of measurable residual disease (MRD) conversion (sHR 0.47, p=0.03) during active treatment, and reduced MRD resurgence (sHR 0.53, p=0.001) versus R. Median duration of MRD negativity was 50.5 months in KR vs. 38 months in R arm. MRD-negative patients had significantly prolonged PFS with KR (HR 0.60, p=0.031); MRD-positive patients benefited from KR mainly during carfilzomib therapy (HR 0.46, p=0.05). The cumulative incidence of second primary malignancies was 6%. In conclusion, long-term follow-up confirms the high effectiveness of KRd-ASCT and KR maintenance. NCT02203643

Autor:innen und Institutionen

  • AOU Città della Salute e della Scienza di Torino, Torino, Italy.
  • Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, Torino, Italy, Torino, Italy.
  • Istituto Nazionale Oncologico Candiolo (INOC) - IRCCS, Candiolo, Italy.
  • ASST Spedali Civili, Brescia, Italy.
  • ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Reggio Emilia, Italy.

ORCID-Profile: Mattia D'Agostino, Delia Rota-Scalabrini, Stelvio Ballanti, Sara Aquino, Paolo De Fabritiis, Francesca Fioritoni, Michele Cea, Francesca Patriarca, Stefania Oliva, Massimo Gentile, Francesca Fazio, Renato Zambello, Sara Bringhen, Paolo Corradini, Benedetto Bruno, Elena Zamagni, Pellegrino Musto

Zitieren

APA

Bertuglia, G., D'Agostino, M., Rota-Scalabrini, D., Belotti, A., Paris, L., Quaresima, M., Morè, S., Ballanti, S., Aquino, S., De Fabritiis, P., Fioritoni, F., Cea, M., Giuliani, N., Patriarca, F., Oliva, S., Gentile, M., Fazio, F., Zambello, R., Bringhen, S., …, & Gay, F. (2026). Carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of the phase 2 FORTE trial. Blood Journal. https://doi.org/10.1182/blood.2026035635

Vancouver

Bertuglia G, D'Agostino M, Rota-Scalabrini D, Belotti A, Paris L, Quaresima M, et al. Carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of the phase 2 FORTE trial. Blood Journal. 2026. doi:10.1182/blood.2026035635

BibTeX
@article{Bertuglia2026,
  author = {Bertuglia, Giuseppe and D'Agostino, Mattia and Rota-Scalabrini, Delia and Belotti, Angelo and Paris, Laura and Quaresima, Micol and Morè, Sonia and Ballanti, Stelvio and Aquino, Sara and De Fabritiis, Paolo and Fioritoni, Francesca and Cea, Michele and Giuliani, Nicola and Patriarca, Francesca and Oliva, Stefania and Gentile, Massimo and Fazio, Francesca and Zambello, Renato and Bringhen, Sara and Corradini, Paolo and Bruno, Benedetto and Zamagni, Elena and Boccadoro, Mario and Musto, Pellegrino and Gay, Francesca},
  title = {Carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of the phase 2 FORTE trial},
  journal = {Blood Journal},
  year = {2026},
  doi = {10.1182/blood.2026035635}
}
Kostenlos starten →